US equities |
INTC $65.39 ▼-28.97% AMZN $237.52 ▼-2.57% MU $896.68 ▼-4.02% NVDA $207.47 ▼-2.90% SNDK $1,216.15 ▼-8.56% AMD $515.80 ▼-8.94% GOOGL $280.20 ▼-1.27% TSLA $395.91 ▼-1.83%
FinancialContent

Qiagen N.V. Common Shares (NY:QGEN)

50.32 -0.02 (-0.04%)
Delayed Quote Updated: 10:10 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Halper Sadeh LLC is Investigating Whether ULBI, QGEN, CCC, PAG are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ultralife Corporation (Nasdaq – ULBI), QIAGEN N.V. (NYSE – QGEN), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether QGEN, VCTR, RLYB are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: QIAGEN N.V. (NYSE – QGEN), Varonis Systems, Inc. (Nasdaq – VRNS), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
QIAGEN reports preliminary Q3 2026 results
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
From QIAGEN N.V.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
From QIAGEN N.V.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
From QIAGEN N.V.
Via Business Wire
News headline image
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V. on Behalf of Qiagen Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
QGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >